Abiopharma

New Form S-3 - enVVeno Medical Corp <b>Filed:</b> 2026-08-21 <b>AccNo:</b> 0001493152-26-039696 <b>Size:</b> 1 MB

New Form SCHEDULE 13G/A - enVVeno Medical Corp <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352645 <b>Size:</b> 11 KB

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medicals Replacement Venous Valve Therapy Compared to Standard of Care Treatments

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical&#8217;s Replacement Venous Valve Therapy Compared to Standard of Care Treatments

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor &#8220;What This Means&#8221; Segment

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series